Do analysts recommend CALT or INDV?

Indivior has a consensus target price of $45.17, suggesting a potential upside of 30.69%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Indivior 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71

Do analysts rate CALT or MANE?

Veradermics has a consensus price target of $153.00, suggesting a potential upside of 56.87%. Given Veradermics' stronger consensus rating and higher probable upside, analysts clearly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veradermics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts rate CALT or OGN?

Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 17.21%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71

Do analysts recommend CALT or GPCR?

Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 135.33%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 2.89

Do analysts recommend CALT or MBX?

MBX Biosciences has a consensus target price of $77.00, indicating a potential upside of 26.37%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MBX Biosciences 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77

Calliditas Therapeutics AB (publ) (CALT) Competitors

$40.00 0.00 (0.00%)

As of 08/31/2026

Compare

CALT vs. INDV, MANE, OGN, GPCR, and MBX

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? Calliditas Therapeutics AB (publ)'s main competitors and comparable companies include Indivior (INDV), Veradermics (MANE), Organon & Co. (OGN), Structure Therapeutics (GPCR), and MBX Biosciences (MBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Indivior has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Indivior	$1.24B	3.29	$210M	$2.79	12.39

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Indivior	26.65%	-283.11%	36.85%

In the previous week, Indivior had 11 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 11 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 1.23 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Indivior	Positive

Indivior has a consensus target price of $45.17, suggesting a potential upside of 30.69%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Indivior has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Veradermics has a consensus price target of $153.00, suggesting a potential upside of 56.87%. Given Veradermics' stronger consensus rating and higher probable upside, analysts clearly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Veradermics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Veradermics	N/A	N/A	N/A

In the previous week, Veradermics had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Veradermics and 0 mentions for Calliditas Therapeutics AB (publ). Veradermics' average media sentiment score of 0.66 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Veradermics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Veradermics	Positive

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Summary

Veradermics beats Calliditas Therapeutics AB (publ) on 8 of the 14 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

In the previous week, Organon & Co. had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Organon & Co. and 0 mentions for Calliditas Therapeutics AB (publ). Organon & Co.'s average media sentiment score of 0.51 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Organon & Co.	Positive

Organon & Co. has a net margin of 3.41% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Organon & Co.'s return on equity of 88.97% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Organon & Co.	3.41%	88.97%	6.03%

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.88

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 17.21%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Organon & Co. beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Structure Therapeutics?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 135.33%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.45, indicating that its share price is 245% less volatile than the broader market.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Structure Therapeutics had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Structure Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Structure Therapeutics' average media sentiment score of 1.33 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Structure Therapeutics	Positive

Structure Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Structure Therapeutics' return on equity of -25.56% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Structure Therapeutics	N/A	-25.56%	-24.31%

Summary

Structure Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to MBX Biosciences?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

MBX Biosciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. MBX Biosciences' return on equity of -26.02% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
MBX Biosciences	N/A	-26.02%	-24.94%

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

MBX Biosciences has a consensus target price of $77.00, indicating a potential upside of 26.37%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, MBX Biosciences had 7 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 7 mentions for MBX Biosciences and 0 mentions for Calliditas Therapeutics AB (publ). MBX Biosciences' average media sentiment score of 1.38 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
MBX Biosciences	Positive

Summary

MBX Biosciences beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALT vs. The Competition

Export

Metric	Calliditas Therapeutics AB (publ)	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$12.06B	$7.15B	$12.83B
Dividend Yield	N/A	2.60%	2.53%	11.78%
P/E Ratio	-21.62	784.69	271.62	24.97
Price / Sales	0.74	760.66	612.99	86.36
Price / Cash	N/A	92.70	77.20	52.85
Price / Book	37.74	11.99	12.92	6.03
Net Income	-$43.96M	$2.82B	$3.47B	$348.89M
7 Day Performance	N/A	1.72%	-0.99%	-2.29%
1 Month Performance	N/A	4.75%	7.14%	2.94%
1 Year Performance	N/A	8.56%	23.90%	14.08%

Calliditas Therapeutics AB (publ) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
INDV Indivior	4.2085 of 5 stars	$35.97 -0.6%	$45.17 +25.6%	+42.3%	$4.27B	$1.24B	12.89	1,051	Positive News
MANE Veradermics	2.7559 of 5 stars	$102.44 +4.0%	$153.00 +49.4%	N/A	$4.11B	N/A	N/A	19	Gap Down
OGN Organon & Co.	1.7832 of 5 stars	$13.76 +0.0%	$11.40 -17.1%	+46.6%	$3.61B	$6.22B	17.86	10,000
GPCR Structure Therapeutics	2.3507 of 5 stars	$49.92 +1.9%	$110.91 +122.2%	+144.2%	$3.41B	N/A	N/A	136	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 9/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. INDV, MANE, OGN, GPCR, and MBX

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Summary

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Summary

How does Calliditas Therapeutics AB (publ) compare to Structure Therapeutics?

Summary

How does Calliditas Therapeutics AB (publ) compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. INDV, MANE, OGN, GPCR, and MBX

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Which has higher earnings & valuation, CALT or INDV?

Do insiders & institutionals hold more shares of CALT or INDV?

Is CALT or INDV more profitable?

Does the media prefer CALT or INDV?

Do analysts recommend CALT or INDV?

Which has more risk and volatility, CALT or INDV?

Summary

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Do analysts rate CALT or MANE?

Is CALT or MANE more profitable?

Does the media refer more to CALT or MANE?

Do insiders and institutionals hold more shares of CALT or MANE?

Which has higher valuation and earnings, CALT or MANE?

Summary

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Does the media prefer CALT or OGN?

Is CALT or OGN more profitable?

Do insiders & institutionals hold more shares of CALT or OGN?

Which has stronger earnings & valuation, CALT or OGN?

Which has more volatility and risk, CALT or OGN?

Do analysts rate CALT or OGN?

Summary

How does Calliditas Therapeutics AB (publ) compare to Structure Therapeutics?

Do analysts recommend CALT or GPCR?

Which has more risk & volatility, CALT or GPCR?

Which has better earnings and valuation, CALT or GPCR?

Do institutionals and insiders have more ownership in CALT or GPCR?

Does the media prefer CALT or GPCR?

Is CALT or GPCR more profitable?

Summary

How does Calliditas Therapeutics AB (publ) compare to MBX Biosciences?

Is CALT or MBX more profitable?

Do institutionals & insiders have more ownership in CALT or MBX?

Which has stronger valuation and earnings, CALT or MBX?

Which has more risk and volatility, CALT or MBX?

Do analysts recommend CALT or MBX?

Does the media favor CALT or MBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools